2026 Q2 -tulosraportti
UUTTA
Tänään
‧42 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 26.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 31.8. | ||
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·11 t sittenI didn't really think there was anything new under the sun in today's presentation, more repetitions of what had been said before, with explanations / clarifications of this. They said there is cash in the bank to cover H127, and they hinted / hoped very much that data would come a good while before the end of H127, which makes good sense as some time is needed to raise capital before the cash box runs completely dry. Personally, I wouldn't be surprised if an investor or a group of investors (with good results, of course) comes in H127, which would mean there won't be an issuance before 2028 or later. They explained their reasons for changing the study in uTreat, and why they are more "silent" than shareholders wish them to be; this was due to several factors, such as legislation, competitors, and delivering correct statistical information. They had also added bowel cancer to their basket trial. (it was mentioned very briefly, so hard to know what to make of it). Did anyone else get anything different / more out of the presentation?
I think a collaboration could be secured soon, but the price is too high, so one postpones with new initiatives , mannitol etc., which of course creates unease and uncertainty that something is wrong. Then the price naturally falls, which a large Investor will of course be happy about. As they say, we need capital and collaboration What I see is what I buy up!! That's my thought, so I hold and buy up 😉
·10 t sitten · MuokattuThey expect to raise new capital only when they have data from studies. Presumably with capital from a partner. If they were to receive an offer for capital before data becomes available, they would naturally look into it. They cannot publish data now as all patients must first complete the study. Plus there are competitive considerations regarding how much should be published at the current time. Patient enrollment for the prostate study is hopefully completed before Christmas. When they have enough patients for the other study depends on when they receive the new approval.@AlfaRomeo156 : good that you mention the patient recruitment for the prostate study, I forgot that. And what they mentioned about them being delayed by a quarter due to them failing to achieve a specific number of patients in the study within a set date, one must assume that this is part of or the entire explanation for why we haven't seen milestone payment(s) from Curium recently. Edit: it is of course under my assumption that everything is going as expected in the study (apart from the extended patient recruitment).
·13 t sittenThe report reduces the very short-term bankruptcy risk, but does not solve the financing problem. With the current burn rate, the cash balance roughly corresponds to about 6–7 months of operation. Therefore, there is a real risk of another capital raise around the turn of the year 2026/27 or at the latest before the loan expires in mid-2027. The report's most important message is therefore: The technology lives, but shareholders are still waiting for the actual clinical proof – and the company may need more money before this proof is available. I see the stock as a binary biotech investment: strong potential upside with good data in the first half of 2027, but high risk of both delays and further dilution before then. The report is not bad enough to destroy the case, but also not strong enough to remove the financial concern.
·14 t sittenIt's really wild how few buy/sell orders there are on it. Buy for 15,000 and it will rise 20% more.....🤩
It will be interesting to see how they account for themselves and talk about the future today. I generally have great faith; both due to the results but also because so many larger investors have put money in. If it goes down below 10, I look forward to buying up.
·2 päivää sittenExciting decision awaits September 11 for Telix and their Pixclara FET-based imaging technology. Could be a market opener for Curasight and validate theranostics. Any thoughts out there regarding the competition for uPar to FET technology? https://nuclionews.com/article/pixclaras-fda-decision-is-two-weeks-away-how-big-could-it-be-for-telixFamiliefar78 I don't know if it was you who asked the question about Pixclara today, but as it emerged, it is not a competitor.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
UUTTA
Tänään
‧42 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·11 t sittenI didn't really think there was anything new under the sun in today's presentation, more repetitions of what had been said before, with explanations / clarifications of this. They said there is cash in the bank to cover H127, and they hinted / hoped very much that data would come a good while before the end of H127, which makes good sense as some time is needed to raise capital before the cash box runs completely dry. Personally, I wouldn't be surprised if an investor or a group of investors (with good results, of course) comes in H127, which would mean there won't be an issuance before 2028 or later. They explained their reasons for changing the study in uTreat, and why they are more "silent" than shareholders wish them to be; this was due to several factors, such as legislation, competitors, and delivering correct statistical information. They had also added bowel cancer to their basket trial. (it was mentioned very briefly, so hard to know what to make of it). Did anyone else get anything different / more out of the presentation?I think a collaboration could be secured soon, but the price is too high, so one postpones with new initiatives , mannitol etc., which of course creates unease and uncertainty that something is wrong. Then the price naturally falls, which a large Investor will of course be happy about. As they say, we need capital and collaboration What I see is what I buy up!! That's my thought, so I hold and buy up 😉
- ·10 t sitten · MuokattuThey expect to raise new capital only when they have data from studies. Presumably with capital from a partner. If they were to receive an offer for capital before data becomes available, they would naturally look into it. They cannot publish data now as all patients must first complete the study. Plus there are competitive considerations regarding how much should be published at the current time. Patient enrollment for the prostate study is hopefully completed before Christmas. When they have enough patients for the other study depends on when they receive the new approval.@AlfaRomeo156 : good that you mention the patient recruitment for the prostate study, I forgot that. And what they mentioned about them being delayed by a quarter due to them failing to achieve a specific number of patients in the study within a set date, one must assume that this is part of or the entire explanation for why we haven't seen milestone payment(s) from Curium recently. Edit: it is of course under my assumption that everything is going as expected in the study (apart from the extended patient recruitment).
- ·13 t sittenThe report reduces the very short-term bankruptcy risk, but does not solve the financing problem. With the current burn rate, the cash balance roughly corresponds to about 6–7 months of operation. Therefore, there is a real risk of another capital raise around the turn of the year 2026/27 or at the latest before the loan expires in mid-2027. The report's most important message is therefore: The technology lives, but shareholders are still waiting for the actual clinical proof – and the company may need more money before this proof is available. I see the stock as a binary biotech investment: strong potential upside with good data in the first half of 2027, but high risk of both delays and further dilution before then. The report is not bad enough to destroy the case, but also not strong enough to remove the financial concern.
- ·14 t sittenIt's really wild how few buy/sell orders there are on it. Buy for 15,000 and it will rise 20% more.....🤩It will be interesting to see how they account for themselves and talk about the future today. I generally have great faith; both due to the results but also because so many larger investors have put money in. If it goes down below 10, I look forward to buying up.
- ·2 päivää sittenExciting decision awaits September 11 for Telix and their Pixclara FET-based imaging technology. Could be a market opener for Curasight and validate theranostics. Any thoughts out there regarding the competition for uPar to FET technology? https://nuclionews.com/article/pixclaras-fda-decision-is-two-weeks-away-how-big-could-it-be-for-telixFamiliefar78 I don't know if it was you who asked the question about Pixclara today, but as it emerged, it is not a competitor.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 26.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 31.8. | ||
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 |
2026 Q2 -tulosraportti
UUTTA
Tänään
‧42 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 26.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 31.8. | ||
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·11 t sittenI didn't really think there was anything new under the sun in today's presentation, more repetitions of what had been said before, with explanations / clarifications of this. They said there is cash in the bank to cover H127, and they hinted / hoped very much that data would come a good while before the end of H127, which makes good sense as some time is needed to raise capital before the cash box runs completely dry. Personally, I wouldn't be surprised if an investor or a group of investors (with good results, of course) comes in H127, which would mean there won't be an issuance before 2028 or later. They explained their reasons for changing the study in uTreat, and why they are more "silent" than shareholders wish them to be; this was due to several factors, such as legislation, competitors, and delivering correct statistical information. They had also added bowel cancer to their basket trial. (it was mentioned very briefly, so hard to know what to make of it). Did anyone else get anything different / more out of the presentation?I think a collaboration could be secured soon, but the price is too high, so one postpones with new initiatives , mannitol etc., which of course creates unease and uncertainty that something is wrong. Then the price naturally falls, which a large Investor will of course be happy about. As they say, we need capital and collaboration What I see is what I buy up!! That's my thought, so I hold and buy up 😉
- ·10 t sitten · MuokattuThey expect to raise new capital only when they have data from studies. Presumably with capital from a partner. If they were to receive an offer for capital before data becomes available, they would naturally look into it. They cannot publish data now as all patients must first complete the study. Plus there are competitive considerations regarding how much should be published at the current time. Patient enrollment for the prostate study is hopefully completed before Christmas. When they have enough patients for the other study depends on when they receive the new approval.@AlfaRomeo156 : good that you mention the patient recruitment for the prostate study, I forgot that. And what they mentioned about them being delayed by a quarter due to them failing to achieve a specific number of patients in the study within a set date, one must assume that this is part of or the entire explanation for why we haven't seen milestone payment(s) from Curium recently. Edit: it is of course under my assumption that everything is going as expected in the study (apart from the extended patient recruitment).
- ·13 t sittenThe report reduces the very short-term bankruptcy risk, but does not solve the financing problem. With the current burn rate, the cash balance roughly corresponds to about 6–7 months of operation. Therefore, there is a real risk of another capital raise around the turn of the year 2026/27 or at the latest before the loan expires in mid-2027. The report's most important message is therefore: The technology lives, but shareholders are still waiting for the actual clinical proof – and the company may need more money before this proof is available. I see the stock as a binary biotech investment: strong potential upside with good data in the first half of 2027, but high risk of both delays and further dilution before then. The report is not bad enough to destroy the case, but also not strong enough to remove the financial concern.
- ·14 t sittenIt's really wild how few buy/sell orders there are on it. Buy for 15,000 and it will rise 20% more.....🤩It will be interesting to see how they account for themselves and talk about the future today. I generally have great faith; both due to the results but also because so many larger investors have put money in. If it goes down below 10, I look forward to buying up.
- ·2 päivää sittenExciting decision awaits September 11 for Telix and their Pixclara FET-based imaging technology. Could be a market opener for Curasight and validate theranostics. Any thoughts out there regarding the competition for uPar to FET technology? https://nuclionews.com/article/pixclaras-fda-decision-is-two-weeks-away-how-big-could-it-be-for-telixFamiliefar78 I don't know if it was you who asked the question about Pixclara today, but as it emerged, it is not a competitor.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt